- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
		
	   		
	   		    
                    
                   	
                   	    4 result(s) found for: Cholinergic urticaria.
                    
                
			
   			
		
		Displaying page 1 of 1.
	
	
| EudraCT Number: 2020-004961-38 | Sponsor Protocol Number: EXP-2177 | Start Date*: 2021-03-22 | |||||||||||
| Sponsor Name:LEO Pharma A/S | |||||||||||||
| Full Title: Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergic urticaria | |||||||||||||
| Medical condition: cholinergic urticaria | |||||||||||||
| 
 | |||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003018-11 | Sponsor Protocol Number: CQGE031E12301 | Start Date*: 2021-10-12 | |||||||||||||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||||||||||||
| Full Title: A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolesce... | |||||||||||||||||||||||
| Medical condition: Chronic Inducible Urticaria | |||||||||||||||||||||||
| 
 | |||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) SI (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2013-002770-43 | Sponsor Protocol Number: CUN-OMAL-UCOL | Start Date*: 2013-10-28 | 
| Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | ||
| Full Title: Multicenter randomized, double-blind, placebo-controlled parallel clinical trial to assess efficacy and safety of Omalizumab (Xolair®) in a new indication: cholinergic urticaria. | ||
| Medical condition: Cholinergic urticaria | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-001262-25 | Sponsor Protocol Number: D-001-02 | Start Date*: 2018-11-21 | 
| Sponsor Name:Charité - Universitätsmedizin Berlin | ||
| Full Title: A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (an... | ||
| Medical condition: Cholinergic urticaria despite H1-antihistamine treatment | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
 .
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
 Query did not match any studies.
    	Query did not match any studies.
     
				
